Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GCAptAIN: Secukinumab in Giant Cell Arteritis
NCT04930094Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2021
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in giant cell arteritis (GCA) (3 arms), sponsored by Novartis. Primary endpoint: Proportion of participants with sustained remission at 52 weeks. Started Oct 2021; status: completed.
02
Drugs
secukinumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT04930094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04930094.